Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Incidence of acute pulmonary embolism, related comorbidities and survival; analysis of a Swedish national cohort

BMC Cardiovascular DisordersBMC series – open, inclusive and trusted201717:155

https://doi.org/10.1186/s12872-017-0587-1

Received: 7 September 2016

Accepted: 2 June 2017

Published: 14 June 2017

Abstract

Background

The aim of the study was to determine the incidence of acute pulmonary embolism (PE) in Sweden and any regional differences. To assess short- and long-term survival analysis after an episode of PE, before and after excluding patients with known malignancies, and to determine the most common comorbidities prior to the PE event.

Methods

All in-hospital patients, including children, diagnosed with acute PE in 2005 were retrieved from the Swedish National Patient Registry (NPR) and incidence rates were calculated. All registered comorbidities from 1998 until the index events were collected and survival up to 4 years after the event were calculated and compared to matched controls.

Results

There were 5793 patients of all ages diagnosed with acute PE in 2005 resulting in a national incidence of 0.6/1000/year. The mean age was 70 years and 52% were women. The most frequent comorbidities were cardiac-, vascular-, infectious- and gastrointestinal diseases, injuries and malignancies. The mortality rates were more than doubled in patients with recent PE compared to that in a matched control group (49.1% vs 21.9%), and the excess mortality remained after exclusion of deaths occurring within one year and after exclusion of patients with any malignancy prior to the event.

Conclusions

PE is associated with high age as well as with multiple comorbidities, and with an increased short- and long-term mortality. This study highlights the importance of a proper follow-up after an acute PE.

Keywords

Pulmonary embolism Incidence Comorbidities Prognosis Sweden

Background

Acute pulmonary embolism (PE) is associated with difficulties in respect to diagnosis, treatment and follow-up. The clinical course is highly variable ranging from asymptomatic to massive embolism with hemodynamic instability, right heart failure and death [1, 2].

PE is associated with serious co-morbidities such as malignancies, ischaemic heart disease and complicated by recurrences and development of post-thrombotic-syndrome [37]. In some cases, the thrombotic process initiates a chronic obstructive process of the pulmonary vessels leading to pulmonary hypertension, e.g. chronic thromboembolic pulmonary hypertension (CTEPH), a disease associated with high morbidity and mortality [8].

Despite being a frequent diagnosis, the incidence of acute PE is still uncertain. Previous studies have reported an annual incidence between 0.2 to 0.8 /1000 where the discrepancy may relate to differences in inclusion criteria [912]. The PE incidence in Sweden is 0.8/1000/year according to one single-centre study [13]. There are no data on regional differences in incidence rates or any north-south gradient in the country.

Today’s knowledge about concomitant diseases related to PE is mostly based on clinical trials and these patients are often not a reflection of the PE patients in real life. Recently, it was reported that venous thromboembolism and pulmonary embolism are often associated with multiple concomitant diseases [14], not least cardiovascular disease, in addition to other well-known associated conditions such as malignancies, recent trauma or surgery and previous venous thromboembolism [1519]

Despite improving diagnostic and treatment regimes, the prognosis after an acute PE is still poor. However, the mortality in PE differs between studies mainly due to differences in the inclusion criteria, such as inclusion of PE only or a combination of any kind of venous thromboembolic disease, inclusion of hemodynamic stable patients or all patients regardless of hemodynamic state, and inclusion of autopsy verified pulmonary embolism or not. Estimates of the short-term mortality rate have varied between 17 to 48% at 30 days [20, 21] and between 19 to 30% for 6 to 12 months [3, 2225]. Studies on long-term prognosis are few, but have indicated that mortality is increased up to 8 years after the acute event [3, 20, 25, 26]. Whether malignancies are responsible for the increased mortality in the long-term setting is unclear [22, 27].

In this study, the Swedish National Inpatient Register (IPR) was used to determine the incidence of acute PE in Sweden and its regional distribution, short- and long-term prognosis and comorbidities with the focus concomitant CVD.

Methods

Subjects

In Sweden, all in-patient care and concomitant data are registered in the Swedish National Inpatient Register (IPR) hosted by the Swedish National Board of Health and Welfare. This register was inaugurated in 1984 and has a national coverage of over 99%, as reporting is mandatory by law, and the validity of IPR has proven to be high [28].

The Swedish modification of ICD (International classification of diseases)-10, ICD-10-SE was used to identify patients with an acute PE as main or subsidiary diagnose during 2005. Altogether 5793 unique persons with a first (during 2005) PE were identified.

A control population was created by the Swedish agency of Statistics, and each unique person with PE was matched with a control person on the basis of age (± 1 day), gender and residency. This was successful in all except 5 cases (very low or very high age, few inhabitants, or incorrect registration). The combined cohort of patients with PE and their matched controls were followed until the 23th of April 2010, and 4107 deaths occurred. Altogether 48 subjects (33 controls and 15 patients) emigrated during the study period.

Methods

From the Swedish NPR, information regarding age, sex, comorbidities and treating hospital were collected. All main and subsidiary inpatient-diagnoses according to ICD-10-SE were collected for each unique PE patient for the period 1998 to the index admission for PE in 2005. From altogether 30,061 admissions (including the index admission), ICD-10-SE codes and dates of admissions were extracted and diagnose groups (e.g. malignancies, ischemic heart disease, stroke etc.) were constructed. For details on diagnose groups and ICD-10-SE codes, see Additional file 1: Table S1. We used the 2007 edition of Nomenclature of Territorial Units for Statistics (NUTS), created by the European Union for statistical purpose, where Sweden is divided in regions according to county. For detail on Swedish regions and counties, see Additional file 2: Figure S1.

Statistics

The national and regional (age-adjusted) incidence rates of acute PE are presented with 95% confidence intervals (CI). Differences based on regional rates and their CIs vs. the national rate are reported. For the survival analysis, date of death, censoring of emigration or being alive 23th of April 2010, whatever occurred first, is reported. The actuarial and Kaplan Mayer’s methods were used. Overall comparisons between groups were tested with log ranks tests. To evaluate the impact of follow-up, the analysis was repeated after 3 months and after 1, 2, and 3 years by analysing the survival of all remaining survivors at each time point. Furthermore, survival within the PE group was analysed stratified for the presence of malignant disease.

The six most common comorbidities in each age group based on age quartiles and stratified for sex are presented as percentage with 95% CIs. The statistical software SPSS 21.0 (IBM, Armonk, NY, USA) was used.

Results

In total, 5793 patients were diagnosed with a main or subsidiary diagnosis of an acute PE in Sweden during 2005, which corresponds to a nation-wide incidence of 0.6/1000/year.

Sixty-nine percent (n = 4003) had acute PE as the main diagnosis.

The age ranged from 1 to 103 years and the mean age was 70.4 years (±15.1 SD). In total, 2788 (48%) were males with a mean age of 72.1 years (±15.3 SD) and 3003 (52%) were females with a mean age of 68.7 years (±14.6 SD). Only 12 patients (0.2%) were younger than 18 years the day of the PE, whereof 10 were over 15 years of age.

The incidence rates stratified for counties are shown in Fig. 1. The counties of Västernorrland, Västerbotten, Östergötland, Skåne and Örebro had rates above the national rate whereas Dalarna, Blekinge, Gävleborg, Södermanland and Norrbotten had rates below. No clear north-south gradient was seen
Fig. 1

Age-adjusted distribution of PE incidence with 95%CI, divided by county. * = Incidence below the national average. ** = Incidence above the national average

The most frequent subsidiary diagnoses registered from 1998 to the index event in 2005 were cardiac diseases, vascular diseases, injuries, malignancies, infectious diseases and gastrointestinal diseases. For definition of groups, see Additional file 1: Table S1 and Tables 1 and 2. Cardiac diseases were the most frequent diagnoses in both men and women and in almost all age groups, and the five most frequent sub-groups were arterial hypertension, arrhythmias, ischaemic heart disease, heart failure, and valvular disease. Within the group vascular diseases, the prevalence of cerebrovascular diseases increased with age in both men and women. The prevalence of inflammatory bowel disease (IBD) was surprisingly low within the group of gastrointestinal diseases. Malignancies and injuries were not further subdivided in this analysis.
Table 1

The six most frequent comorbidities registered stratified by age men

 

Age quartiles (years)

Disease groups

−60.9

61–71.9

72–80.9

81-

Cardiac diseases

24 (20–27)

48 (44–52)

60 (57–64)

73 (70–76)

 Hypertensive diseases

11 (9–13)

25 (21–28)

30 (26–33)

29 (25–32)

 Ischemic heart diseases

6 (4–7)

17 (14–19)

27 (24–31)

36 (33–40)

 Arrhythmias

7 (5–9)

17 (14–20)

23 (20–26)

34 (30–37)

 Heart failure

3 (2–4)

10 (8–12)

21 (18–24)

35 (32–39)

 Valvular diseases (nonrheumatic)

1 (0–2)

2 (1–3)

3 (2–4)

5 (4–7)

 Other cardiac diseases

4 (3–6)

4 (3–6)

4 (2–5)

5 (3–7)

Vascular diseases

28 (25–31)

33 (30–37)

34 (31–38)

38 (34–41)

 Cerebrovascular diseases

4 (3–6)

10 (8–13)

14 (12–17)

20 (17–23)

 Other arterial diseases

3 (2–4)

4 (3–6)

5 (4–7)

7 (5–9)

 Other venous diseases

22 (19–25)

21 (18–24)

16 (13–19)

15 (12–18)

 Other vascular diseases

0 (0–1)

1 (0–2)

3 (1–4)

4 (3–6)

Gastrointestinal diseases

18 (15–21)

21 (18–24)

24 (21–27)

30 (27–34)

 Inflammatory bowel diseases

3 (2–4)

2 (1–3)

2 (1–3)

2 (1–3)

Infectious diseases

23 (20–26)

30 (26–33)

34 (30–37)

43 (39–46)

Injuries

18 (16–21)

20 (17–23)

22 (19–25)

31 (28–34)

Malignancies

17 (14–19)

30 (26–33)

28 (25–32)

22 (19–25)

Numbers shown are percentages with (95% confidence intervals). The ICD-10-SW codes used for defining the disease groups were following: hypertensive diseases 110–115, Ischemic heart diseases 120–125, heart failure 150, valvular diseases 133–139, and other cardiac diseases 105–108, 127–128, 130–131, 140–143, 151. Vascular diseases included cerebrovascular diseases 160–169, other arterial diseases 170–179, other venous diseases 180–189 and other vascular diseases 195–199. Gastrointestinal diseases were defined by K00-K93 whereof inflammatory bowel diseases by K50-K52. Infectious diseases included A00-B99 and J00-J22, injuries 500–599 and T00-T99, and malignanciesC01-C97

Table 2

The six most frequent comorbidities registered stratified by age women

 

Age quartiles (years)

Disease groups

−60.9

61–71.9

72–80.9

81-

Cardiac diseases

22 (19–25)

52 (48–55)

65 (62–68)

71 (68–74)

 Hypertensive diseases

11 (9–13)

30 (26–33)

38 (34–41)

33 (29–36)

 Ischemic heart diseases

6 (4–7)

19 (16–22)

27 (24–31)

34 (30–37)

 Arrhythmias

5 (3–6)

16 (13–18)

24 (21–27)

34 (31–38)

 Heart failure

2 (1–3)

12 (9–14)

23 (20–26)

36 (33–39)

 Valvular diseases (nonrheumatic)

1 (0–2)

2 (1–4)

3 (2–4)

5 (3–7)

 Other cardiac diseases

4 (3–5)

4 (2–5)

4 (2–5)

3 (2–4)

Vascular diseases

22 (19–25)

27 (23–30)

32 (29–35)

33 (30–36)

 Cerebrovascular diseases

4 (3–5)

10 (8–13)

15 (13–18)

17 (15–20)

 Other arterial diseases

3 (2–4)

4 (3–6)

5 (4–7)

7 (5–9)

 Other venous diseases

16 (14–19)

14 (11–16)

14 (12–17)

13 (11–16)

 Other vascular diseases

1 (0–1)

1 (0–2)

3 (2–4)

3 (2–4)

Gastrointestinal diseases

19 (16–22)

23 (20–26)

27 (24–30)

31 (27–34)

 Inflammatory bowel diseases

3 (2–5)

2 (1–3)

2 (1–3)

2 (1–3)

Infectious diseases

24 (21–27)

28 (25–32)

35 (37–39)

39 (35–42)

Injuries

19 (16–22)

23 (20–27)

27 (24–30)

42 (38–45)

Malignancies

27 (24–30)

28 (25–31)

71 (68–74)

15 (12–17)

Numbers shown are percentages with (95% confidence intervals). The ICD-10-SW codes used for defining the disease groups were following: hypertensive diseases 110–115, Ischemic heart diseases 120–125, heart failure 150, valvular diseases 133–139, and other cardiac diseases 105–108, 127–128, 130–131, 140–143, 151. Vascular diseases included cerebrovascular diseases 160–169, other arterial diseases 170–179, other venous diseases 180–189 and other vascular diseases 195–199. Gastrointestinal diseases were defined by K00-K93 whereof inflammatory bowel diseases by K50-K52. Infectious diseases included A00-B99 and J00-J22, injuries 500–599 and T00-T99, and malignanciesC01-C97

Notably, 1141 (20%) patients did not have any registered episode of in-patient care between 1998 and 2005.

Until 23th April 2010, 2841 (50%) patients died, whereas 1266 (22%) of the matched controls died, thus demonstrating a more than doubled mortality rate in patients with a recent PE (p < 0.001), see Fig. 2. During the first 3 months, 1204 (21%) patients died and 77 (1.3%) control subjects died. After exclusion of these early deaths, 1637 of 4587 (36%) patients died and 1189 of 4712 (25%) controls died (p < 0.001) from three months and onwards, see Fig. 3. This procedure was repeated after 1, 2 and 3 years and each analysis showed higher mortality rate in PE patients vs. controls (all p < 0.001). The excess mortality amongst PE patients remained after exclusion of all patents with a subsidiary diagnosis of any malignant disease (p < 0.001), see Fig. 4.
Fig. 2

Kaplan-Meier curve demonstrating survival after an acute PE compared to an age-sex- and location matched control group. Log-Rank Test: p = <0.001

Fig. 3

Kaplan-Meier curve demonstrating survival starting 90 days after an acute PE, compared to an age-sex- and location matched control group. Log-Rank Test: p = <0.001

Fig. 4

Kaplan-Meier curve demonstrating survival after an acute PE and with no previous history of malignancy, compared to age-sex- and location matched control group. Log-Rank Test: p = <0.001

Discussion

We found a nation-wide incidence of PE of 0.6 per thousand person years in Sweden, which is in line with previous reports [912, 21, 22, 29]. Previous estimates have, like ours, been based on retrospective data from hospital records and varying estimates could be explained by varying inclusion criteria. There are challenges to estimate the true the incidence of PE, as the estimated number of unreported cases is likely to be substantial. We do suspect that information from nursing homes and long term care facilities are not found in central registers and our study, like many other, shows that the incidence of PE is strongly correlated to increasing age [9, 10, 22, 29]. Furthermore, the symptoms related to an acute PE are unspecific and mimic most cardiovascular and pulmonary diseases, and the autopsy rate in many countries, like in Sweden, is steadily declining. It should also be emphasised that the events in this study are not validated vs. hospital records.

To our knowledge, the regional differences in incidence of PE in Sweden have not been demonstrated previously. There was no clear-cut difference between the northern part vs. the southern part, neither was there any clear difference between counties with low vs. high populations density and the observed differences were thus probably not due to access to medical care. However, the differences could illustrate local traditions and merits future studies. The play of chance is of course also a possibility.

The mean age at baseline for the Swedish PE population in 2005 was 70 years emphasising that PE is a common disease in elderly persons and will probably increase with increasing longevity. Females had a higher incidence rate than males and lower median age at baseline. Oral contraceptives, pregnancy, and the post-partum period are risk factor for venous thromboembolism, which may contribute to the lower median age of pulmonary embolism amongst woman [3033].

Approximately 80% of all PE patients had had at least one episode of in-patient care during the preceding 8 years before the index event and cardiovascular diseases were by far the most common comorbidity registered. Although there are proposed links between arterial cardiac disease and PE [3, 6, 7], this study cannot answer whether the prevalence of IHD is higher in the PE population or not, as we do not have comorbidities registered in the control population. Within the group vascular diseases, venous diseases were the most frequent which is expected as deep venous thrombosis (DVT) and PE are manifestations of the same disease and more than 50% of DVT patients have a simultaneous PE at presentation [34]. Notably, the frequency of DVT is probably underestimated as these patients are diagnosed and treated as out-patients and are not captured by the in-patient register. Registered gastrointestinal diseases were common in patients with a future PE and surprisingly, inflammatory bowel disease (IBD) was not commonly registered. IBD has previously been linked to PE [1719], but may in our study be underreported since most of these patients are treated as outpatients. We conclude that 20% of the patients did not have any registered episodes of in-hospital care before the index event of PE. Our interpretation is that one fifth of the PE population is healthy before the index event and are thus not eligible for prophylactic measures. However, we cannot exclude that these patients had concomitant diseases only requiring outpatient contacts with the health system. There were no major differences in registered comorbidities between men and women.

The short-term (3 months) and long-time survival rates in this Swedish national cohort of PE patients corresponds well with previous reports [3, 20, 2226]. We show that PE patients have reduced survival compared to the background population even after excluding early deaths and malignancies. This highlights that the PE population needs careful follow-up. Notably, previous studies have reported inconclusive results regarding the survival of PE patients without any known malignancy [22, 27].

The strengths of this report are the size of this national wide cohort and the completeness as no patients were excluded due to age and comorbidities. However, there are some limitations to be noted. The in-hospital diagnoses of PE were not validated and we have no data on patients with PE treated as out-patients. And the size of the unrecognised PE population as discussed above is not known. The control group was well matched, but unfortunately we do not have data on comorbidities in the control population. Subsequent morbidity and causes of death after the index PE (e.g. diagnosis of a malignancy shortly after the PE) merit further analyses.

Conclusion

In summary, the incidence of acute PE in Sweden was estimated to be 0.6/1000/year and it is increasing with age. There where no major regional differences in incidence rates and no clear north-south gradient. The six most common comorbidities were cardiac-, vascular-, gastrointestinal-, and infectious diseases, injuries and malignancies, with no major differences between males and females. There was a clear increase in mortality in the PE population compared to a matched control-group and the difference remained after exclusion of deaths during the first three months, and after exclusion of patients with known malignancy. This highlights the importance of a proper structural follow-up after an episode of acute PE, a diagnosis still associated with a poor prognosis.

Abbreviations

CI: 

Confidence Interval

CTEPH: 

Chronic Thromboembolic Pulmonary Hypertension

CVD: 

Cardiovascular Disease

DVT: 

Deep Venous Thrombosis

HF: 

Heart Failure

IBD: 

Inflammatory Bowel Disease

ICD: 

International Classification of Diseases

IHD: 

Ischemic Heart Disease

NPR: 

National Patient Registry

NUTS: 

Nomenclature of Territorial Units for Statistics

PE: 

Pulmonary Embolism

VTE: 

Venous Thromboembolism

Declarations

Acknowledgements

The authors are grateful to Camilla Ring and Bo Carlberg for important contributions regarding data collection and manuscript revising.

Availability of data and materials

The dataset generated and analysed during the current study are not publicly available due to participant identifying factors but are available from the corresponding author on reasonable written request.

Competing interests

The authors declare that they have no competing interests.

Consent for publications

Not applicable.

Funding

Dr. Söderberg has received research grants from Actelion Pharmaceuticals Ltd. and the Swedish Association of pulmonary hypertension (SveFPH).

Dr. Andersson has received unrestricted financial support from the Västerbotten County Council (ALF).

Authors’ contributions

SS designed and supervised the study and data collection. TA analysed and interpreted the data and drafted the manuscript. Both authors have read and approved the final manuscript.

Ethics approval and consent to participate

The regional ethics review board in Umea, Sweden approved the study. Furthermore, the ethical board at the Swedish National Board of Health and Welfare and the Swedish agency of Statistics reviewed and approved extraction of data from the Swedish NPR.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Public Health and Clinical Medicine, Medicine, Umea University

References

  1. Stein PD, Beemath A, Matta F, et al. Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED II. Am J Med. 2007;120:871–9.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J. 2000; 21: 1301–36.Google Scholar
  3. Klok FA, Zondag W, van Kralingen KW, et al. Patient outcomes after acute pulmonary embolism. A pooled survival analysis of different adverse events. Am J Respir Crit Care Med. 2010;181:501–6.View ArticlePubMedGoogle Scholar
  4. Schulman S, Lindmarker P, Holmstrom M, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost. 2006;4:734–42.View ArticlePubMedGoogle Scholar
  5. Eichinger S, Weltermann A, Minar E, et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med. 2004;164:92–6.View ArticlePubMedGoogle Scholar
  6. Sorensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet. 2007;370:1773–9.View ArticlePubMedGoogle Scholar
  7. Klok FA, Mos IC, Broek L, et al. Risk of arterial cardiovascular events in patients after pulmonary embolism. Blood. 2009;114:1484–8.View ArticlePubMedGoogle Scholar
  8. Pengo V, Lensing AW, Prins MH, et al. Thromboembolic pulmonary hypertension study G. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350:2257–64.View ArticlePubMedGoogle Scholar
  9. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585–93.View ArticlePubMedGoogle Scholar
  10. Oger E. Incidence of venous thromboembolism: a community-based study in western France. EPI-GETBP study group. Groupe d'Etude de la thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83:657–60.PubMedGoogle Scholar
  11. Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013; 126: 832 e13–21.Google Scholar
  12. Huang W, Goldberg RJ, Anderson FA, Kiefe CI, Spencer FA. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). Am J Med. 2014;127:829–39. e5View ArticlePubMedPubMed CentralGoogle Scholar
  13. Johansson M, Johansson L, Lind M. Incidence of venous thromboembolism in northern Sweden (VEINS): a population-based study. Thromb J. 2014;12:6.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Cohen AT, Gitt AK, Bauersachs R, et al. The management of acute venous thromboembolism in clinical practice. Thromb Haemost: Results from the European PREFER in VTE Registry; 2017. doi:https://doi.org/10.1160/TH16-10-0793.Google Scholar
  15. Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med. 2007;167:935–43.View ArticlePubMedGoogle Scholar
  16. Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol. 2010;56:1–7.View ArticlePubMedGoogle Scholar
  17. Ocak G, Vossen CY, Verduijn M, Dekker FW, Rosendaal FR, Cannegieter SC, et al. Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. J Thromb Haemost. 2013;11:116–23.Google Scholar
  18. Leizorovicz A, Turpie AG, Cohen AT, Wong L, Yoo MC, Dans A, Group SS. Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART study J Thromb Haemost. 2005;3:28–34.Google Scholar
  19. Tapson VF. Acute pulmonary embolism. N Engl J Med. 2008;358:1037–52.View ArticlePubMedGoogle Scholar
  20. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med. 1999;159:445–53.View ArticlePubMedGoogle Scholar
  21. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International cooperative pulmonary embolism Registry (ICOPER). Lancet. 1999;353:1386–9.View ArticlePubMedGoogle Scholar
  22. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5:692–9.View ArticlePubMedGoogle Scholar
  23. Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, et al. The clinical course of pulmonary embolism. N Engl J Med. 1992;326:1240–5.Google Scholar
  24. Kniffin WD Jr, Baron JA, Barrett J, Birkmeyer JD, Anderson FA Jr. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med. 1994;154:861–6.View ArticlePubMedGoogle Scholar
  25. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med. 1991;151:933–8.Google Scholar
  26. Flinterman LE, van Hylckama VA, Cannegieter SC, Rosendaal FR. Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors. PLoS Med. 2012;9:e1001155.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Reitter SE, Waldhoer T, Mayerhofer M, Eigenbauer E, Ay C, Kyrle PA, et al. Long-term survival of patients with a history of venous thromboembolism. Ann Hematol. 2011;90:585–94.Google Scholar
  28. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.Google Scholar
  29. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008;28:370–2.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med. 2008;359:2025–33.View ArticlePubMedGoogle Scholar
  31. Kujovich JL. Hormones and pregnancy: thromboembolic risks for women. Br J Haematol. 2004;126:443–54.View ArticlePubMedGoogle Scholar
  32. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143:697–706.View ArticlePubMedGoogle Scholar
  33. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194:1311–5.View ArticlePubMedGoogle Scholar
  34. Girard P, Decousus M, Laporte S, Buchmuller A, Herve P, Lamer C, Group PS. Diagnosis of pulmonary embolism in patients with proximal deep vein thrombosis: specificity of symptoms and perfusion defects at baseline and during anticoagulant therapy. Am J Respir Crit Care Med. 2001;164:1033–7.Google Scholar

Copyright

© The Author(s). 2017

Advertisement